Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Simcere Pharmaceutical Group

http://en.simcere.com/

Latest From Simcere Pharmaceutical Group

China Drug Makers Brace As Anti-Graft Campaign Impact Surfaces

Bookmark
  • Analysis
By Dexter Yan

Simcere, Hengrui, and Zai Lab are among the first Chinese pharma firms to report various forms of impact from the gathering storm of a national anti-corruption campaign launched in July in the healthcare and pharma sectors.

China Compliance

Sosei Builds APAC Independence Through Idorsia Deal

Bookmark
  • Analysis
By Ian Haydock and Lisa Takagi

Sosei Heptares' acquisition of Idorsia's ex-China APAC operations will give the Japan-UK group ready-made independent development and commercialization capabilities in Japan, accelerating by "five to 10 years" its goals in its home market, its CEO tells Scrip. The deal also brings a marketed drug and options to selected Idorsia pipeline assets. 

Japan Asia Pacific

Almirall Plots M&A Moves Ahead Of Lebrikizumab Approval

Bookmark
  • News
By Kevin Grogan

The Spanish group has been fairly quiet on the dealmaking front of late but the proceeds of a significant capital raise have been earmarked to help “swiftly execute inorganic growth opportunities.”

M & A Dermatology

Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's

Bookmark
  • News
By Ian Haydock, Jung Won Shin, Lisa Takagi, Dexter Yan, Anju Ghangurde and Joseph Haas

Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Jilin Boda Pharmaceutical Co., Ltd.
    • ChinaVax
    • Master Luck Corporation Limited
    • Jiangsu Simcere Pharmaceutical R&D Co., Ltd.
    • Jiangsu Yanshen Biological Technology Stock Co., Ltd.
    • Nanjing Tung Chit Pharmaceutical Co., Ltd.
    • Shandong Simcere Medgenn Bio-Pharmaceutical Co. Ltd.
    • Wuhu Zhong Ren Pharmaceutical Co. Ltd.
    • Xiangao Investment Company Ltd.
    • Yantai Medgenn Co. Ltd.
    • Jiangsu Simcere Pharmaceutical Co., Ltd.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By